Highest-materiality recent filing
Aardvark reports Q2 net loss $14.4M; ARD-101 clinical hold, HERO/OLE terminated
Cash $73.9M as of Jun 30, 2026 vs $91.2M at Mar 31; funds operations into late 2027.
FDA places full clinical hold on Aardvark's ARD-101 IND; HERO and OLE trials paused
FDA full clinical hold on IND for ARD-101, affecting Phase 3 HERO trial (AVK-101-301) and OLE trial (AVK-101-302).
Aardvark Q1 net loss $21.6M; ARD-101/ARD-201 programs on voluntary pause
Net loss of $21.6M for Q1 2026 vs. $9.3M for Q1 2025, driven by higher R&D expenses.
Aardvark enters $150M equity distribution agreement with Piper Sandler
May sell up to $150M of common stock at market through Piper Sandler as agent.
Net loss $57.6M for FY2025 vs $20.6M in FY2024; cash $110.0M supports operations into Q2 2027.
Aardvark Therapeutics pauses Phase 3 HERO trial for ARD-101 in PWS due to cardiac signals
Voluntary pause of Phase 3 HERO trial (NCT06828861) and open-label extension (NCT07197034) for ARD-101 in Prader-Willi Syndrome.
Aardvark COO exits to lead new dermatology subsidiary; CFO Sun adds COO role
Bryan Jones stepped down as COO of Aardvark on Feb 9, 2026, to become CEO of wholly-owned subsidiary Ardia Therapeutics.
Aardvark Therapeutics expands Phase 3 HERO trial age eligibility to 7+ years for ARD-101 in PWS
IRB approved amended protocol lowering minimum age from 10 to 7 years for Phase 3 HERO trial evaluating ARD-101.
Aardvark doses first patient in Australia Phase 3 HERO trial; Q3 2026 data readout on track
First patient dosed in Australia in Phase 3 HERO trial for ARD-101 for hyperphagia in Prader-Willi syndrome.
Aardvark Therapeutics Q3 net loss $16.3M; cash $126.4M; FDA expands PWS trial age to 10 years
Cash, equivalents, and short-term investments of $126.4M as of Sep 30, 2025; expected to fund operations into 2027.
ARD-201 (ARD-101+sitagliptin) in DIO mice reduced body weight ~19% in 30 days, comparable to high-dose tirzepatide, and preserved lean mass.
Aardvark gets FDA alignment to lower Phase 3 PWS trial min age to 10
FDA aligned on protocol amendment for Phase 3 HERO trial of ARD-101, lowering minimum age from 13 to 10 years old.
Net loss of $14.4M in Q2 2025 vs $5.4M in Q2 2024; R&D expenses rose to $13.1M.
Aardvark reports ARD-201 preclinical data: 19% weight loss in mice; plans two Phase 2 trials
ARD-201 monotherapy achieved ~19% body weight reduction in DIO mice after 30 days.
Aardvark Therapeutics reports FY 2024 net loss $20.6M; advances ARD-101 Phase 3 PWS trial
Net loss $20.6M in 2024 vs $7.2M in 2023; R&D expenses $17.4M (up $12.9M YoY).
Aardvark Therapeutics completes IPO; issues 5.888M shares at $16.00, raises $94.2M gross
IPO of 5,888,000 shares at $16.00 per share completed on Feb 14, 2025.
On October 6, 2026, the board of directors (the “Board”) of Aardvark Therapeutics, Inc. (the “Company”) appointed David (Zhongwei) Zhang, Ph.D., MBA, as a Class II director of the Company, effective October 7, 2026.
Max materiality 0.90 · Median 0.65 · Most common event other_material